The effects of the synthetic 28-amino-acid ct-human atrial natriuretic peptide (ANP) on 
D eBold et al' first demonstrated that infu-
sions of extracts from atrial muscle caused natriuresis and diuresis and systemic hypotension in anesthetized rats. Currie et a12 subsequently demonstrated that atrial extracts caused dose-dependent relaxation of rabbit aortic strips. Subsequent studies have characterized the aminoacid sequence of atrial natriuretic peptide (ANP).
Biologically active ANP exists in several different chain lengths derived from a 151-152-amino-acid precursor.3-9 Studies from Schwartz et al10 and Sugawara et al"l have suggested that the circulating forms of ANP in rats and humans are 28-amino-acids in length.
Many studies have demonstrated that ANP relaxes vascular strips in a variety of organ systems and animal species. ANP also relaxes preconstricted denuded epicardial coronary artery rings from explanted hearts of patients.12 It is believed to act via activation of particulate guanylate cyclase,13 and ANP-induced smooth muscle relaxation in vitro14 has been related to cyclic guanosine monophosphate (cGMP) formation. Results from studies examining the effects of ANP on the intact coronary vasculature have, however, been conflicting. [15] [16] [17] [18] Studies from our laboratory'9 in chronically instrumented awake dogs demonstrated that bolus injection of ANP (10-150 ,ug) into the left atrium induced dose-related, sustained proximal coronary dilation. Relatively brief dose-related increases in phasic coronary blood flow were also noted, indicating transient resistance artery dilation. The proximal coronary dilation induced by ANP was not related to the transient increases in coronary flow and was not altered by blockade of the autonomic nervous system. The direct dilation effects of ANP on the epicardial vessels were similar to those of nitrates but developed more gradually and were not accompanied by significant changes in systemic hemodynamics. More recent studies from our laboratory in conscious dogs have further demonstrated that ANP dilates intramural coronary arteries during ischemic stimulation in the presence of a critical stenosis, causing redistribution of blood flow to the ischemic subendocardium. 20 In normal subjects, intravenous infusion of ANP (0.01-0.10 ,ug/kg/min) induced significant diuresis and natriuresis and decreases in pulmonary capillary wedge pressure with no significant alterations in heart rate, mean arterial pressure, or cardiac index.21 In patients with congestive heart failure, comparable doses of ANP increased cardiac index and stroke volume index, significantly reduced pulmonary capillary wedge pressure and systemic vascular resistance, but did not change heart rate or mean arterial pressure; the natriuresis and diuresis effects were attenuated. Studies have not examined the effects of ANP on the coronary arterial vasculature in patients. Accordingly, the present study was designed to evaluate the effects of ANP on the proximal coronary arteries and coronary blood flow in humans.
Methods

Patient Selection and Preparation
The study comprised male patients less than 70 years old undergoing routine coronary angiography at the Durham Veterans Administration Medical Center. Patients with unstable angina, acute myocardial infarction, evidence of pulmonary edema, or recent heart failure were excluded. Informed consent was obtained from each patient before the study. Patients with left main coronary disease or significant (>75%) three-vessel disease documented during catheterization were also excluded. A total of 17 patients were evaluated. The experimental protocol and consent forms were previously reviewed and approved by the Institutional Review Board and conformed with the ethical guidelines prescribed by the National Institutes of Health, including the provision of suitable explanation to human subjects or their guardians concerning the experimental design and all significant hazards. Informed consent was obtained the day before the cardiac catheterization and study protocol. The experimental use of the synthetic 28-amino-acid a-human ANP in our institution has been approved by the US Food and Drug Administration for use in this study (IND No. 30556 ).
Patients were admitted at least 24 hours before the study and continued on maintenance medications, including diuretics, (3-blockers, and digoxin.
All vasodilators including long-acting nitrates, calcium channel blockers, and converting enzyme inhibitors were withheld for more than 24 hours before the study. Diuretics were withheld on the day of the study.
Experimental Protocol
The patients were studied in the cardiac catheterization laboratory in the supine position. Right heart catheterization was performed with a balloontipped 7F Swan Rad, Pittsburgh, Pennsylvania) at a constant speed of 4 ml/sec, with a constant volume of 7 ml and under a constant injection pressure of 800 psi. At least 10 minutes was allowed between injections. Digital images were acquired at a rate of 1 image per cardiac cycle gated to the R wave. Images were stored in unsubtracted format in a 512x512 matrix. A 1-cm grid was imaged at the location of the patient at the conclusion of the study for distance calibration. Subsequently, images were analyzed with a Philips APU image analysis system. Coronary diameter quantitation was performed with a combined edge-detection and densitometric profile measurement algorithm developed in our laboratory. The coronary segment at the site of the Doppler crystal was chosen for quantitation. In six patients, duplicate control images were obtained at 2-minute intervals to assess the reproducibility of the quantitative angiographic system. The accuracy of the quantitative angiographic system was also assessed by comparing the diameter measurements obtained from images of contrast-filled Lucite phantoms to actual diameters.
After the control images were obtained, the 28-amino-acid a-human ANP (Peninsula Laboratories, Inc, Belmont, California) (2. Figure 2 . The measured diameters show good agreement with actual diameters over a range of 1.0-5.0 mm (r=0.99, SEE=0.10). Figure 3 is a representative coronary angiogram in one patient before and 30 minutes after ANP injection. Coronary dilation is clearly evident throughout the epicardial vessels.
The top portion of Figure 4 illustrates the average diameter and percent change in diameter of the proximal coronary artery of all 17 patients before and at serial intervals after ANP injection. ANP induced significant (15%) proximal coronary dilation from 3.49±0.57 to 3.99±0.68 mm at 5 minutes. Figure 5 . Although mean coronary flow (calculated from flow velocity measurements after correction for diameter changes) increased 18% from 87t55 to 102t54 vol flow units at 5 minutes after ANP injection, the increase was not statistically significant. The lack of a significant increase in flow indicates that the proximal coronary dilation was a direct effect induced by ANP and was not secondary to flow-mediated changes.
Discussion
The present study demonstrates that in patients, bolus injections of ANP (2.5 gg/kg) caused sustained preferential epicardial coronary dilation without accompanying significant sustained increases in coronary blood flow. The epicardial coronary dilation was not further increased by a subsequent large dose of nitroglycerin. The striking sustained epicardial coronary dilation was associated with brief minor reductions in mean aortic pressure and left ventricular end-diastolic pressure and minor increases in heart rate and cardiac output. ANP is believed to mediate its effects via activation of particulate guanylate cyclase closely associated with the cell membrane.13 cGMP formation has been reported to generally correlate with the vasorelaxant activity in vitro.14 In the present study, we observed that the duration of epicardial dilation was related more closely to the duration of elevation of plasma cGMP than the duration of increase in plasma ANP levels. In recent preliminary studies in chronically instrumented awake dogs,30 we demonstrated a similar relation between plasma cGMP levels and epicardial coronary dilation. Discordance between duration of epicardial dilation and the much shorter duration of plasma ANP elevation was also observed. Furthermore, in previous studies,30 we demonstrated a selective increase in plasma cGMP with ANP, an activator of particulate guanylate cyclase. In contrast, activators of soluble guanylate cyclase, including nitroglycerin and endothelium-derived relaxing factor, did not increase plasma cGMP despite a similar or greater epicardial coronary dilation. Gerzer et a131 studied the effects of bolus injections of 50 jig ANP in eight normal subjects. They also observed a short-lived threefold increase in plasma ANP that rapidly returned to baseline within 10 minutes. As in our present study, plasma cGMP elevation was more sustained, lasting more than 30 minutes. The authors suggested that cGMP may be a biological marker for circulating ANP in humans, although a direct correlation with a physiologic response such as rate and duration of diuresis, natriuresis, or vasodilation was not studied. Our data demonstrate for the first time an in vivo relation between the elevated plasma cGMP level and epicardial coronary dilation in humans. This relation may be selective for conductance vessels because both coronary flow and arterial pressure changes were much more brief than the duration of plasma cGMP elevation or duration of epicardial coronary dilation. The correlation between plasma cGMP elevation and the duration of epicardial dilation does not necessarily indicate that the dilation was induced by the plasma cGMP. In fact, the plasma cGMP was probably from sources other than the vascular smooth muscle such as the endothelium. Our demonstration in animal studies30 of a selective increase in plasma cGMP in response to ANP but not activators of soluble guanylate cyclase such as nitroglycerin or endothelium-derived relaxing factor further lends support to the notion that the plasma cGMP itself is not the cause of the dilation. The actual mediator of the dilation may be an increase in cGMP production in the vascular smooth muscle.12 The present study does not establish a cause-and-effect relation between epicardial dilation and changes in plasma cGMP. It also has not established that the increase in plasma cGMP was related to changes in cGMP in vascular smooth muscle. However, the data do indicate continuous production of cGMP during the period of epicardial coronary dilation and thus provide support for the view that cGMP may be mediating the dilation.
Because ANP shares certain vascular effects of nitrates, it has been considered as an "endogenous nitrate." 32, 33 It is tempting to speculate that ANP may play an important role in the response to ischemia. Myocardial ischemia may cause an increase in ventricular filling pressures and both left and right atrial pressures. The increase in atrial pressures stretches atrial myocytes and increases ANP release, which may, in turn, reduce ischemia by dilation of the stenotic epicardial coronary arteries and increasing total flow and/or dilation of intramural coronary arteries, leading to favorable redistribution of flow to the ischemic subendocardium.20 The ANP dose (2.5 
